Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer

PURPOSE: To characterize the pharmacokinetics (PK) of pertuzumab and trastuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer in the randomized, double-blind, phase III JACOB study (NCT01774786), and to evaluate the appropriateness of the pertuzumab regimen i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirschbrown, Whitney P., Wang, Bei, Nijem, Ihsan, Ohtsu, Atsushi, Hoff, Paulo M., Shah, Manish A., Shen, Lin, Kang, Yoon-Koo, Alsina, Maria, Girish, Sandhya, Garg, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682857/
https://www.ncbi.nlm.nih.gov/pubmed/31183514
http://dx.doi.org/10.1007/s00280-019-03871-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682857/
https://www.ncbi.nlm.nih.gov/pubmed/31183514
http://dx.doi.org/10.1007/s00280-019-03871-w

Ejemplares similares